HIGHLIGHTS
- who: Xiao-Feng Xie from the (UNIVERSITY) have published the research: Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial, in the Journal: (JOURNAL) of March/31,/2021
- what: All patients provided written informed consent for use of the medical information for research purpose.
- how: All data were analyzed using SPSS 23.0 statistical software (SPSS Inc []. A randomized phase II trial which was designed to assess the efficacy and tolerability of pyrotinib plus capecitabine . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.